ACE2 News and Research

RSS

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

15 Sep 2020

Computational models screen for coronaviruses likely to infect humans

The researchers from Rochester Institute of Technology and the Hauptmann-Woodward Medical Research Institute produced models of the receptor-binding domain (RBD) found on outbreak strains of betacoronaviruses and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

14 Sep 2020

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020

Study sheds light on the disproportionate impact of COVID-19 on Blacks

In a study published in JAMA today, Mount Sinai researchers report findings that shed some light on the disproportionate impact of COVID-19 on Blacks, who have experienced rates of infection and death that are much greater, in some areas twice and three times more, than their proportion of the population.

11 Sep 2020

Researchers say Influenza may increase risk of COVID-19

A recent study by researchers suggests that the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is influenced by influenza virus infection during the initial period of coronavirus disease 2019 (COVID-19) pandemic in Europe. The study is currently available on the medRxiv preprint server.

10 Sep 2020

Scientists explain how SARS-CoV-2 attacks the brain

Now, a team of scientists at Yale University revealed the changes that happen in the brain caused by SARS-CoV-2, the virus that has caused over 27.86 million people and claimed over 903,000 lives.

10 Sep 2020

Vapers, smokers, and non-smokers with chronic conditions have higher risks for COVID-19

What do vapers, smokers, and non-smokers with chronic conditions such as high blood pressure or diabetes have in common? They all are at higher risk for COVID-19.

10 Sep 2020

Computer-designed proteins can protect lab-grown human cells from SARS-CoV-2

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

10 Sep 2020

Study: Small proteins block interaction between SARS-CoV-2 and human cell receptor

Using innovative computer-based approaches, researchers have developed protein inhibitors that block the interaction between the SARS-CoV-2 virus and human cell receptor ACE2.

10 Sep 2020

Brain inflammation seen in fatal COVID-19 cases

Now, a new study by researchers at the Barts Health NHS Trust and the University of Cambridge in the United Kingdom shows that some patients develop neurological complications tied to COVID-19.

9 Sep 2020

Susceptibility to SARS-CoV-2 infection varies across bat species

A recent study by researchers at Wuhan University, China, reveals that many bat species are not potential carriers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of genetic mutations in angiotensin-converting enzyme 2 (ACE2) that prevent the entry of viruses inside bat cells. The study is currently available on the bioRxiv* preprint server.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Host gene editing main driving force of SARS-CoV-2 mutations

A new study published on the aRxiv preprint server in September 2020 shows that the host immune response, mediated by two RNA editors, causes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adapt and change strain characteristics.

9 Sep 2020

Tel Aviv University receives philanthropic grant from 3M for COVID-19 vaccine research

Science-based technology company 3M has awarded a significant philanthropic research grant of $400,000 to the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University to advance scientific knowledge in the global response to the COVID-19 pandemic.

8 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Researchers at Karolinska Institutet in Sweden have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells.

4 Sep 2020

ACE2 News and Research

New antibody assay for COVID-19 promises sensitive mass-scale detection

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Computational models screen for coronaviruses likely to infect humans

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

Study sheds light on the disproportionate impact of COVID-19 on Blacks

Researchers say Influenza may increase risk of COVID-19

Scientists explain how SARS-CoV-2 attacks the brain

Vapers, smokers, and non-smokers with chronic conditions have higher risks for COVID-19

Computer-designed proteins can protect lab-grown human cells from SARS-CoV-2

Study: Small proteins block interaction between SARS-CoV-2 and human cell receptor

Brain inflammation seen in fatal COVID-19 cases

Susceptibility to SARS-CoV-2 infection varies across bat species

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Host gene editing main driving force of SARS-CoV-2 mutations

Tel Aviv University receives philanthropic grant from 3M for COVID-19 vaccine research

Limited gut inflammation in COVID-19

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Study: Small neutralizing antibody can block SARS-CoV-2 from entering human cells

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News